8|0|Public
50|$|<b>Brodimoprim</b> is a {{structural}} derivative of trimethoprim. In <b>brodimoprim,</b> the 4-methoxy group of trimethoprim is {{replaced with a}} bromine atom.|$|E
50|$|As trimethoprim, <b>brodimoprim</b> is a {{selective}} inhibitor of bacterial dihydrofolate reductase.|$|E
40|$|Combinations {{of either}} <b>brodimoprim</b> or {{trimethoprim}} plus either carbenicillin, gentamicin, ciprofloxacin or rifampicin showed synergy at sub-inhibitory concentrations against both Enterococcus faecalis NCTC 5957 and 775. <b>Brodimoprim</b> alone and in combination showed greater antibacterial activity against both strains of E. faecalis than trimethoprim. MBCs of <b>brodimoprim</b> and trimethoprim were 14. 4 and 25. 6 mg/L for E. faecalis NCTC 5957 and 7. 2 and 12. 8 mg/L for E. faecalis NCTC 775. Combinations of either <b>brodimoprim</b> or trimethoprim plus the other antibacterial agents, except gentamicin and dibromopropamidine isethionate, were bactericidal at achievable plasma concen-trations. Viable count determinations of cultures of both test organisms {{in the presence}} of 3 / 4 of the MIC of each of the four antibiotics and the two antifolates alone and combinations of each antibiotic with either <b>brodimoprim</b> or trimethoprim indicated that only the combinations prevented recovery and regrowth of the cultures over 24 h. The ATP released from cultures of both strains of E. faecalis treated with <b>brodimoprim</b> and tnmethoprim at the same concentrations was approximately 1. 5 times greater with <b>brodimoprim</b> than with trimethoprim. Combinations of 3 / 4 of the MIC of each of the antibiotics in combination with 3 / 4 of the MIC of <b>brodimoprim</b> against cultures of both strains of E. faecalis resulted in greater release of ATP than occurred with equivalent trimethoprim combinations. It is postulated that the increased activities observed with the <b>brodimoprim</b> combinations resulted from an effect of <b>brodimoprim</b> on the bacterial cell permeability control. These results indicate that both <b>brodimoprim</b> and trimethoprim offer potential benefits for use with either carbenicillin, gentamicin, ciprofloxacin or rifampicin for the treatment of E. faecalis infections...|$|E
40|$|The {{entry of}} an {{antibiotic}} into phagocytes {{is a prerequisite}} for its intracellular bioactivity against susceptible facultative or obligatory intracellular microorganisms. <b>Brodimoprim</b> is a dimethoxybenzylpyrimidine that has recently entered into clinical use, and its uptake into and elimination from human polymorphonuclear neutrophils (PMNs), together with its effects on normal phagocytic and antimicrobial mechanisms, have been investigated. <b>Brodimoprim</b> uptake by PMNs was determined by a velocity-gradient centrifugation technique under various experimental conditions and was expressed as the ratio of the intracellular to the extracellular drug concentration (C/E) in comparison with the C/E of trimethoprim, which was used as a control drug. After incubation with 7. 5 mg of <b>brodimoprim</b> per ml, PMNs accumulated <b>brodimoprim</b> (C/E, 74. 43 6 12. 35 at 30 min) more avidly than trimethoprim (C/E, 20. 97 6 6. 61 at 30 min). The cellular uptake of <b>brodimoprim</b> was not affected by temperature, 2, 4 -dinitrophenol, or potassium fluoride and was increased with an increase in the pH of the medium. It was reduced in formaldehyde-killed PMNs. The efflux of <b>brodimoprim</b> was very rapid (46 % after 5 min). The liposolubility of <b>brodimoprim</b> was about three times that of trimethoprim, as was the uptake. Therefore, a possible passive transmembrane diffusion mechanism might be proposed. <b>Brodimoprim</b> did not decrease either phagocytosis or phagocyte-mediated bactericidal activity, nor did it affect oxidative burst activity, as investigated by luminol-amplified chemiluminescence. On the basis of the pharmacokineti...|$|E
40|$|Dipalmitoylphosphatidylcholine vesicles {{were used}} as a {{biological}} membrane model to investigate the interaction and the permeation properties of trimethoprim and <b>brodimoprim</b> {{as a function of}} drug protonation. The drug-membrane interaction was studied by differential scanning calorimetry. Both drugs interacted with the hydrophilic phospholipid head groups when in a protonated form. An experiment on the permeation of the two drugs through dipalmitoylphosphatidylcholine biomembranes showed higher diffusion rate constants when the two drugs were in the uncharged form; lowering of the pH (formation of protonated species) caused a reduction of permeation. Drug uptake by human neutrophil cells was also investigated. Both drugs may accumulate within neutrophils; however, <b>brodimoprim</b> does so to a greater extent. This accumulation is probably due to a pH gradient driving force, which allows the two drugs to move easily from the extracellular medium (pH approximately 7. 3) into the internal cell compartments (acid pH). Once protonated, both drugs are less able to permeate and can be trapped by the neutrophils. This investigation showed the importance of the physicochemical properties of <b>brodimoprim</b> and trimethoprim in determining drug accumulation and membrane permeation pathways...|$|E
40|$|The {{activities}} of the 2, 4 -diamino- 5 -benzylpyrimidines <b>brodimoprim</b> and metioprim against anaerobic bacteria were tested alone and in combination with sulfonamides. Alone they were two to four times more active than trimethoprim, but in combination with sulfonamides, their activity was slightly {{lower than that of}} trimethoprim plus sulfamethoxazole...|$|E
40|$|In an open study, 172 {{male and}} female adult {{patients}} with acute uncomplicated bacterial cystitis were randomly allocated to three treatment groups. Two groups received <b>brodimoprim</b> 200 mg tablets as follows: a single dose of two 200 mg tablets on day 1, followed by one tablet per day on days 2 and 3 (58 patients); or a single daily dose of two tablets, for 2 days (63 patients). The third group received a single dose of pefloxacin, as two 400 mg tablets, for 1 day (51 patients). Complete urinalysis, sediment and urine culture examinations were carried out before treatment and 10 days after the last dose. Evaluation also comprised, {{at the time of}} enrolment and 48 h after the last dose, measurement of corporal temperature and assessment of symptoms (dysuria, pollakiuria, strangury, suprapubic pain, burning sensation during urination and urgency) on a 4 -point scale. The eradication rate for the pathogen concerned was 98. 3 % and 96. 7 % in the groups receiving <b>brodimoprim</b> for 3 and 2 days, respectively, and 92. 8 % in the pefloxacin group (between-group comparison n. s.). There was significant regression of symptoms (P < 0. 001) in the three groups (between-groups comparison n. s.). Mainly gastrointestinal adverse events occurred in 3 patients receiving <b>brodimoprim</b> for 2 days and in 4 patients from each of the other two groups...|$|E
40|$|Pasteurella multocida und Mannheimia haemolytica sind gram {{negative}} Bakterien der Familie Pasteurellaceae, die eine weltweit verbreitete und ökonomisch wichtige Erkrankung bei Rindern, die Enzootische Bronchopneumonie, verursachen. Die im Rahmen dieser Arbeit untersuchten Expressionsprofile von diesen beiden Erregern nach der Behandlung für 10 bzw. 30 min mit acht unterschiedlichen Antibiotika (Novobiocin, Enrofloxacin, Florfenicol, Tilmicosin, Cefquinom, Rifampicin, Trimethoprim und <b>Brodimoprim),</b> bildete ein bis dato einzigartiges Referenzkompendium zur Erforschung des MoAs einer antibiotischen Substanz mit unbekannten MoA (Thiazin). Ferner bildete dieses Referenzkompendium eine Grundlage für die Charakterisierung der Expressionsprofile des halbsynthetischen Naturstoffes C- 30 mit vermuteter Virulenzabschwächender Wirkung. Die für die microarray Auswertung eingesetzte optimierte Datenbearbeitung beinhaltete eine globale cluster-Analyse, eine fingerprint-Analyse, die Ermittlung der genomweiten Genregulation und der Regulation der Expression der Zielgene, sowie die Identifikation von Antibiotika spezifischen Signaturgenen. Zur Übersichtlichkeit der Auswertung und der Erörterung der Ergebnisse wurde ein Schwerpunkt auf die Expressionsprofile von P. multocida gelegt. Mittels cluster-Analyse wurden die P. multocida Expressionsprofile in fünf cluster eingeteilt, wobei die Antibiotika mit ähnlichen MoA, mit Ausnahme von Enrofloxacin und Cefquinom, separate Gruppen bildeten. Enrofloxacin und Cefquinom verursachten einen geringen Effekt auf das Transkriptom von P. multocida, wobei nur etwa 1 % des Genoms beeinflusst wurde. Hingegen wurden 20 % des Genoms durch die restlichen getesteten Antibiotika Florfenicol, Tilmicosin, Rifampicin, Trimethoprim und <b>Brodimoprim</b> reguliert. Novobiocin wirkte außergewöhnlich stark und regulierte 40 % des P. multocida Genoms. Eine Regulation der Zielgene wurde bei Novobiocin (DNA Gyrase), Rifampicin (RNA Polymerase), Florfenicol (Ribosom) und Tilmicosin (Ribosom) festgestellt. Die Inhibitoren der Folatbiosynthese (Trimethoprim und <b>Brodimoprim),</b> der Inhibitor der DNA Gyrase (Enrofloxacin) und der Inhibitor der Zellwandbiosynthese (Cefquinom) verursachten dagegen keine Regulation der Zielgene. Die Signaturgene, die durch einzelne Antibiotika spezifisch reguliert worden waren, wurden für alle untersuchten Antibiotika identifiziert. Die Aufnahme der Expressionsprofile zweier eng verwandter Bakterien zielte auf die einzigartige Möglichkeit, durch Vergleich der Regulation orthologer Gene, Hinweise auf den MoA einer neuen Substanz zu bekommen. Es zeigte sich allerdings, dass zum Teil große Unterschiede in der transkriptionellen Antwort beider Bakterien auf Antibiotika-Behandlung existieren, die zur Vorsicht bei einer vergleichenden MoA Analyse mahnen. Die Transkription vieler Virulenzgene, insbesondere solcher, die in Kapselbiosynthese und Kapseltransport, LPS Biosynthese, Kompetenz, Adhärenz und Eisenaufnahme involviert sind, wurde durch die Antibiotika beeinflusst. Dabei wurde die Expression generell reprimiert. Das lässt vermuten, dass der therapeutische Effekt der Antibiotika auf einer Kombination von Wachstumshemmung und Virulenzabschwächung beruht. Novobiocin und Trimethoprim verursachten eine deutliche Reprimierung der Kapselgene von P. multocida, was in der Tat zu einer reduzierten Ausbildung der Kapsel führte. Für Florfenicol konnte allerdings kein Zusammenhang zwischen Kapselgenregulation und Verringerung der Kapsel gezeigt werden. Mit Hilfe des Referenzkompendiums wurden die Thiazin-induzierten Expressionsprofile von M. haemolytica und P. multocida untersucht. Thiazin ist eine antibiotisch hochwirksame Substanz für Pasteurellaceae, deren Wirkmechanismus noch nicht bekannt ist. Die Thiazin-induzierten Expressionsprofile in M. haemolytica und P. multocida führten nicht zu konkreten Hinweisen auf das Zielprotein oder die Zielproteine. Allerdings lässt die Tatsache, dass die Thiazin-induzierten Expressionsprofile keine Ähnlichkeiten zu den Expressionsprofilen des Referenzkompendiums zeigten, auf einen neuen Wirkmechanismus schließen. Zu den möglichen Kandidaten für das Zielprotein oder die Zielproteine von Thiazin wurden die 18 orthologe Gene, die in beiden Bakterien induziert wurden, gezählt. Diese globale Transkriptom-Analyse stellt nur einen ersten Schritt dar, der durch biochemische und molekularbiologische Studien begleitet werden muss. Die Wirkung von C- 30, einem halogenierten Furanon, wurde ebenfalls untersucht. Dabei zeigte sich, dass C- 30 die Transkription einer ähnlichen Anzahl von Virulenzgenen beeinflusste, wie die Substanzen des Referenzkompendiums. Von 165 potentiellen P. multocida Virulenzgenen wurden 23 durch C- 30 (10 µM) reguliert. Darunter waren Gene, die für die Protease ClpB und die Katalase HtkE kodieren, sowie zwei weitere Gene aus dem Eisentransportsystem (exbB und exbD). Pasteurella multocida and Mannheimia haemolytica are {{gram negative}} bacteria {{of the family}} Pasteurellaceae. Both are the causative agents of bovine respiratory disease, a highly contagious infection, which causes significant economic losses to beef industry worldwide. The transcriptional response of P. multocida and M. haemolytica to eight antibiotics with known mode of actions (MoAs) was recorded to create a compendium of transcriptional profiles for MoA studies. Data analysis included the identification of regulated genes, a global cluster and fingerprint analysis, {{as well as the}} identification of antibiotic-specific signature genes and altered virulence genes. Furthermore, the compendium of transcriptional profiles was compared with the profiles of two substances with unknown MoA. A thiazin antibiotic and a furanone virulence factor inhibitor were investigated. The data analysis focused mainly on the P. multocida reference compendium. At minimal inhibitory concentration the three bactericidal compounds enrofloxacin, cefquinome and the novel thiazin compound had a minor impact on gene regulation with approximately 1 % of the P. multocida genome affected, whilst the bacteriostatic compounds florfenicol, tilmicosin, rifampin, trimethoprim and <b>brodimoprim</b> regulated approximately 20 % of the genome. The bacteriostatic antibiotic novobiocin was particular by regulating 40 % of all P. multocida genes. Regulation of target genes was observed for novobiocin, rifampin, florfenicol and tilmicosin and signature genes were identified for all antibiotics. Comparative analysis of gene expression between two related bacteria family Pasteurellaceae is a powerful method to draw conclusions about the distinctive as well as similar characteristics between these species. The reference compendium for P. multocida and M. haemolytica represents the unique basis for the MoA determination of new antimicrobial compounds. Comparing the transcriptional response between these two bacteria revealed the differences of global expression profiles and also differences in the alterations of orthologous genes expression. These results helped to elucidate the MoA of potential antimicrobial drug candidate thiazin. The transcription of many P. multocida virulence factors, particularly genes involved in capsule synthesis and export, LPS synthesis, competence, adherence and iron transport was altered in the presence of antibiotics. Virulence gene transcription was mainly negatively affected, however also the opposite effect was observed, like the up-regulation of the tad locus involved in tight adherence by rifampin. Novobiocin and trimethoprim caused a strong decrease in the transcription of capsule genes, which correlated with a concomitant reduction of the capsular layer on the surface of P. multocida. The broad negative impact on virulence gene transcription supports the notion that the therapeutic effect of some antibiotics could be a combination of growth and virulence inhibition. The thiazin compound is a new anti-infective compound against Pasteurellaceae and the MoA of this compound is unknown. In both bacteria P. multocida and M. haemolytica the thiazin induced transcriptional profiles were unrelated to the reference compendium profiles pointing to a new MoA. In both bacteria 18 orthologous genes were induced by thiazin. Following the notion that target genes often are induced upon an antibiotic assault, these upregulated genes could represent possible target proteins. However the global transcriptome analysis represents a first step to determine the MoA of new compounds which must be followed by biochemical and genetic studies. The effect of the furanone C- 30 was also analyzed. The transcription of a similar number of virulence genes was altered by C- 30 as compared to the antibiotics of the reference compendium. For instance in case of P. multocida the expression of 23 virulence genes was regulated by 10 µM C- 30 after 10 min. These genes code for a ClpB protease and HtkE Katalase, as well as for two proteins of iron uptake system (exbB and exbD) ...|$|E

